Reaction
Atrophic Vulvovaginitis reporting signals
As of the last recalculation, Atrophic Vulvovaginitis appears in 719 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is ALENDRONATE SODIUM (PRR 66.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alendronate Sodium | 175 | 66.0 | 66.1 |
| Raloxifene Hydrochloride | 25 | 51.3 | 51.4 |
| Risedronate Sodium | 43 | 42.5 | 42.6 |
| Exemestane | 27 | 37.9 | 37.9 |
| Conjugated Estrogens | 69 | 37.8 | 37.8 |
| Estrogens, Conjugated | 69 | 37.1 | 37.2 |
| Chlorhexidine Gluconate | 11 | 35.4 | 35.4 |
| Estradiol | 77 | 28.8 | 28.8 |
| Telmisartan | 16 | 26.5 | 26.5 |
| Anastrozole | 32 | 26.4 | 26.4 |
| Linagliptin | 16 | 26.0 | 26.0 |
| Anastrozole Tablets | 18 | 24.9 | 24.9 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 19 | 23.9 | 23.9 |
| Letrozole | 41 | 20.4 | 20.4 |
| Estradiol Gel 0.1% | 25 | 16.6 | 16.6 |
| Estradiol Transdermal | 25 | 16.5 | 16.6 |
| Alpelisib | 4 | 13.4 | 13.4 |
| Pertuzumab | 11 | 11.9 | 11.9 |
| Medroxyprogesterone Acetate | 17 | 10.1 | 10.1 |